Y. Yazici Et Al. , "Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called efficacy and safety trials: a survey of power considerations," RHEUMATOLOGY , vol.47, no.7, pp.1054-1057, 2008
Yazici, Y. Et Al. 2008. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called efficacy and safety trials: a survey of power considerations. RHEUMATOLOGY , vol.47, no.7 , 1054-1057.
Yazici, Y., Adler, N. M., & Yazici, H., (2008). Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called efficacy and safety trials: a survey of power considerations. RHEUMATOLOGY , vol.47, no.7, 1054-1057.
Yazici, Y., N. M. Adler, And H. Yazici. "Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called efficacy and safety trials: a survey of power considerations," RHEUMATOLOGY , vol.47, no.7, 1054-1057, 2008
Yazici, Y. Et Al. "Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called efficacy and safety trials: a survey of power considerations." RHEUMATOLOGY , vol.47, no.7, pp.1054-1057, 2008
Yazici, Y. Adler, N. M. And Yazici, H. (2008) . "Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called efficacy and safety trials: a survey of power considerations." RHEUMATOLOGY , vol.47, no.7, pp.1054-1057.
@article{article, author={Y. Yazici Et Al. }, title={Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called efficacy and safety trials: a survey of power considerations}, journal={RHEUMATOLOGY}, year=2008, pages={1054-1057} }